Company Filing History:
Years Active: 2024
Title: Christopher Ecker: Innovator in Cancer Treatment
Introduction
Christopher Ecker is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of immunology, particularly in the development of T cells with improved functionality. His innovative work focuses on enhancing the efficacy of immune cells in cancer treatment.
Latest Patents
Christopher Ecker holds a patent for T cells engineered to inhibit the endogenous expression of one or more of Blimp-1 and A20, and/or overexpress one or more of exogenous TCF7 and Bach2. This patent outlines methods for treating cancer by administering these modified immune cells. Additionally, it describes methods for increasing the peak fold proliferation rate, killing efficiency, and inducing cellular characteristics associated with the naïve phenotype of immune cells. The patent also details the generation of modified immune cells through the introduction of exogenous constructs encoding CAR or TCR, while inhibiting the expression of Blimp-1 and A20.
Career Highlights
Christopher Ecker is currently associated with Kite Pharma, Inc., a company known for its pioneering work in cell therapy. His research and innovations have positioned him as a key figure in the advancement of cancer therapies.
Collaborations
He has collaborated with notable colleagues such as Saikat Banerjee and Yoonjung Shin, contributing to the collective efforts in enhancing cancer treatment methodologies.
Conclusion
Christopher Ecker's innovative work in the field of immunology and cancer treatment exemplifies the impact of engineering T cells for improved functionality. His contributions continue to pave the way for advancements in therapeutic approaches to combat cancer.